<div id="readability-page-1"><div> By Elias Schisgall <pre></pre> Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue. Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year. The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier. Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior. The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said. Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share. The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22. <pre></pre> Write to Elias Schisgall at elias.schisgall@wsj.com <pre></pre> (END) Dow Jones Newswires March 13, 2026 14:48 ET (18:48 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

Capricor Therapeutics 的股价下跌 8.6%，至 30.54 美元，此前报告第四季度亏损 3020 万美元，远超分析师预期的 50 万美元收入和每股亏损 51 美分。该公司在本季度没有产生任何收入，较去年同期的 1110 万美元下降。Capricor 正在等待 FDA 对 Deramiocel 治疗杜氏肌营养不良症的批准，预计将在 2026 年 8 月 22 日之前收到回复

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

MorningStar

Capricor治疗

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

Capricor 治疗公司因第四季度亏损幅度超出预期而股价下跌